View Cart  

Japan: PMDA to Accept Trials From China, South Korea

A A
Japan’s Pharmaceutical and Medical Devices Agency (PMDA) cited increasing regulatory cooperation with China and South Korea in saying it will now accept new drug applications that rely on well-designed, well-conducted global clinical trials in the neighboring East Asian nations. The decision to accept trial results from China and Korea builds on regulatory cooperation between Japan, the U.S. and EU, the PMDA said.
Clinical Trials Advisor